Representative image.
| Photo Credit: Getty Images/iStockphoto
The Union Health Ministry has proposed amendments to the Drugs Rules, 1945, to immediately suspend the manufacturing licences of drugs declared Not of Standard Quality (NSQ) on specified critical quality parameters.
The government said on Wednesday (November 4, 2026) that the proposed amendments seek to enable prompt regulatory intervention upon detection of substandard medicines, prevent their continued manufacture and distribution, and strengthen the mechanism for ensuring compliance with prescribed quality standards, in the interest of patient safety and public health.
Under the existing provisions of the Drugs Rules, 1945, suspension or cancellation of a manufacturing licence is preceded by the prescribed regulatory procedure, including issuance of a show-cause notice. This may result in a time gap between the declaration of a drug as NSQ and the initiation of regulatory action. During this period, the drug may remain in circulation, posing potential risks to public health and making effective recall more challenging.
To address this regulatory concern, the Ministry has proposed a provision for immediate suspension of the manufacturing licence of the drug by the Central Licensing Approving Authority or the State Licensing Authority upon receipt of a government analyst’s report declaring the drug as NSQ with respect to assay, dissolution, related substances, impurities or sterility.
“These parameters are critical to determining the quality of medicines. The proposed provision aims to ensure that instances of non-compliance involving these specified parameters are met with prompt regulatory action, thereby minimising potential risks to patients,’’ the Ministry said.
The proposed amendment provides for mandatory corrective measures before revocation of the suspension. The suspension shall continue until the manufacturer undertakes an effective root cause analysis to identify the reasons for the quality failure and implements appropriate Corrective and Preventive Action (CAPA) to the satisfaction of the licensing authority.
Suspension can be revoked after the requisite corrective and preventive measures are implemented and then verified by the licensing authority. This mechanism will ensure that identified quality deficiencies are adequately addressed and necessary safeguards are put in place to prevent their recurrence.
“To further strengthen regulatory coordination and facilitate timely action, consequential amendments have also been proposed to Form 13, relating to the test report of the Government Analyst. Under the proposed mechanism, the Government Analyst’s report would be endorsed to the Drugs Controller General of India (DCGI), the concerned State/UT Licensing Authority under whose jurisdiction the manufacturing site is located, as well as the manufacturer and marketer of the concerned drug,’’ the government said.
It added that the proposed arrangement is aimed at ensuring timely communication of NSQ findings to the relevant authorities and stakeholders, thereby facilitating coordinated regulatory action and strengthening accountability across the drug manufacturing and marketing chain.
The proposed amendments follow deliberations at the 65th meeting of the Drugs Consultative Committee, held on December 20, 2024, and recommendations of the 92nd meeting of the Drugs Technical Advisory Board, held on April 24, 2025.
The amendments are expected to strengthen post-marketing regulatory surveillance, facilitate timely action against substandard medicines, promote greater accountability among manufacturers and marketers, and reinforce public confidence in the quality of medicines available in the country.
The draft amendments have been notified for public consultation, inviting objections and suggestions from stakeholders and members of the public within 30 days from the date on which copies of the Gazette of India containing the draft rules are made available to the public.
Published – November 05, 2026 01:23 am IST
